BAA contract titled, "advancement of integrated continuous manufacturing (ICM)unit operations."

Ended Definitive Contract Awarded Last action

Contract number
HHSF223201610104C
Awardee
Awarding agency
Obligated
$4,400,000

Award facts

Opportunity
Contract value 100% obligated
$4,400,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Woburn, MA 01801, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Additional Work (new agreement, FAR part 6 applies) 1 $180,108
Original award $4,219,892

About this award

The U.S. Food and Drug Administration (FDA) awarded a $4,400,000.00 Cost Plus Fixed Fee contract to Continuus Pharmaceuticals, Inc. to support the "ADVANCEMENT OF INTEGRATED CONTINUOUS MANUFACTURING (ICM) UNIT OPERATIONS." This definitive contract does not have a set-aside designation and is scheduled to be completed by September 29, 2019. The contract is part of the FDA's efforts to advance integrated continuous manufacturing unit operations, which is a major program focus area for the agency.

Quick answers

Who was awarded contract HHSF223201610104C?

HHSF223201610104C was awarded to Continuus Pharmaceuticals, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 8, 2016.

How much is contract HHSF223201610104C worth?

The government has obligated $4,400,000 on HHSF223201610104C.

Was contract HHSF223201610104C competed?

The extent of competition for HHSF223201610104C was full and open competition. The government received 8 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award